Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Surg Innov ; 24(6): 543-551, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28877644

RESUMO

BACKGROUND: To investigate the early and late antiadhesive effect and any changes of fibrin matrix regulation enzymes on rat peritoneum, after local administration of bevacizumab. METHODS: Rats were subjected to cecal abrasion. Bevacizumab (5 mg/kg) against placebo was given intraperitoneally. On the 2nd, 14th, and 28th postoperative days adhesions were scored, and tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), matrix metalloproteinase-9 (MMP-9), degree of fibrosis, and angiogenesis were measured in abrased cecum and in intact parietal peritoneum. RESULTS: Bevacizumab significantly reduced adhesions up to 15% on the 2nd, 52.5% on the 14th, and 55% on the 28th postoperative day, and significantly increased tPA concentrations in peritoneum. PAI-1 was decreased, and a significantly higher tPA/PAI-1 ratio along with an increase of MMP-9 was measured at all time points. Fibrosis and angiogenesis were significantly lower on the 14th and 28th postoperative days. CONCLUSIONS: Local bevacizumab administration has a strong early and late antiadhesive action on rat peritoneum, mediated by changes in the tPA/PAI-1 and MMP balance in favor of fibrinolysis up to 28 days after operations.


Assuntos
Inibidores da Angiogênese/farmacologia , Bevacizumab/farmacologia , Ceco/efeitos dos fármacos , Fibrinólise/efeitos dos fármacos , Peritônio/efeitos dos fármacos , Aderências Teciduais/prevenção & controle , Animais , Ceco/patologia , Masculino , Metaloproteinase 9 da Matriz/metabolismo , Peritônio/patologia , Inibidor 1 de Ativador de Plasminogênio/metabolismo , Ratos , Ratos Wistar , Ativador de Plasminogênio Tecidual/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...